C
ZNTL icon

Covestor’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Covestor’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51
Closed – – 2846
2025
Q4 		$0 Sell
51
-1
-2% -$1 ﹤0.01% 2816
2025
Q3 		$0 Hold
52
– – ﹤0.01% 2861
2025
Q2 		$0 Buy
52
+29
+126% +$38 ﹤0.01% 2831
2025
Q1 		$0 Hold
23
– – ﹤0.01% 2802
2024
Q4 		$0 Buy
23
+2
+10% +$7 ﹤0.01% 2820
2024
Q3 		$0 Buy
21
+14
+200% +$51 ﹤0.01% 2849
2024
Q2 		$0 Hold
7
– – ﹤0.01% 2837
2024
Q1 		$0 Buy
7
+3
+75% +$41 ﹤0.01% 2820
2023
Q4 		$0 Sell
4
-1
-20% -$15 ﹤0.01% 2797
2023
Q3 		$0 Hold
5
– – ﹤0.01% 2793
2023
Q2 		$0 Hold
5
– – ﹤0.01% 2734
2023
Q1 		$0 Hold
5
– – ﹤0.01% 2665
2022
Q4 		$0 Sell
5
-1
-17% -$22 ﹤0.01% 2684
2022
Q3 		$0 Sell
6
-4
-40% -$109 ﹤0.01% 2698
2022
Q2 		$0 Buy
10
+2
+25% +$53 ﹤0.01% 2428
2022
Q1 		$0 Sell
8
-2
-20% -$108 ﹤0.01% 2479
2021
Q4 		$1K Buy
+10
New +$774 ﹤0.01% 2002

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Covestor's ZNTL Position: Q1 2026 in Review

Covestor sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 51 shares.

Covestor first reported a position in ZNTL in Q4 2021 and held it in 17 quarters. The position peaked at $1K in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Covestor reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Covestor sold 51 Zentalis Pharmaceuticals shares in Q1 2026.
  • Covestor first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 17 quarters.
  • Covestor's Zentalis Pharmaceuticals position peaked at $1K in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.